Weiss G R, Green S, Hannigan E V, Boutselis J G, Surwit E A, Wallace D L, Alberts D S
University of Texas Health Science Center, San Antonio.
Gynecol Oncol. 1990 Dec;39(3):332-6. doi: 10.1016/0090-8258(90)90262-j.
Forty-one eligible patients with metastatic or recurrent carcinoma of the uterine cervix received 149 courses of carboplatin. The drug was administered at a starting dosage of 400 mg/m2 IV every 28 days. The overall response rate was 15% (two complete responses, four partial responses; 95% confidence interval 6-29%) and response durations were 2.0, 2.0, 2.5 +, 2.5+, 5.25 +, and 6.75 months. The major toxic effects included nausea and vomiting in 48% of courses, anemia in 47%, leukopenia in 38%, and thrombocytopenia in 22%. The activity of carboplatin against advanced cervical cancer is modest and similar to the activity of cisplatin alone. However, the toxicity profile of carboplatin is substantially better than that of cisplatin and warrants exploration of this agent against cervix cancer in more aggressive regimens or in combination with other agents.
41例符合条件的转移性或复发性子宫颈癌患者接受了149个疗程的卡铂治疗。药物起始剂量为400mg/m²，静脉注射，每28天一次。总缓解率为15%（2例完全缓解，4例部分缓解；95%置信区间6-29%），缓解持续时间分别为2.0、2.0、2.5+、2.5+、5.25+和6.75个月。主要毒副作用包括48%的疗程出现恶心和呕吐，47%出现贫血，38%出现白细胞减少，22%出现血小板减少。卡铂对晚期宫颈癌的活性一般，与单用顺铂的活性相似。然而，卡铂的毒性特征明显优于顺铂，值得在更积极的方案中或与其他药物联合探索其对宫颈癌的治疗作用。
